Repligen Co. (NASDAQ:RGEN) – Analysts at First Analysis cut their Q2 2017 earnings estimates for shares of Repligen in a research report issued on Tuesday. First Analysis analyst now expects that the biotechnology company will earn $0.15 per share for the quarter, down from their previous estimate of $0.16. First Analysis has a “Equal Weight” rating and a $40.00 price target on the stock. First Analysis also issued estimates for Repligen’s Q4 2017 earnings at $0.13 EPS, FY2017 earnings at $0.57 EPS, Q1 2018 earnings at $0.16 EPS and FY2018 earnings at $0.72 EPS.
Separately, Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a report on Thursday, May 11th.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/05/25/q2-2017-eps-estimates-for-repligen-co-rgen-cut-by-analyst.html.
Repligen (NASDAQ:RGEN) opened at 38.90 on Wednesday. The company has a market cap of $1.33 billion, a P/E ratio of 102.64 and a beta of 1.58. The company has a 50-day moving average of $36.76 and a 200 day moving average of $33.10. Repligen has a 52 week low of $21.11 and a 52 week high of $39.96.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.02. The business had revenue of $30.59 million for the quarter, compared to analyst estimates of $29.28 million. Repligen had a net margin of 6.89% and a return on equity of 10.16%. The firm’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same quarter last year, the business posted $0.12 EPS.
In related news, Director Thomas F. Ryan, Jr. sold 4,000 shares of the company’s stock in a transaction on Monday, March 20th. The shares were sold at an average price of $34.83, for a total transaction of $139,320.00. Following the completion of the sale, the director now directly owns 12,594 shares in the company, valued at approximately $438,649.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Jon Snodgres sold 1,909 shares of the company’s stock in a transaction on Friday, March 17th. The shares were sold at an average price of $34.91, for a total transaction of $66,643.19. Following the sale, the chief financial officer now owns 23,789 shares of the company’s stock, valued at $830,473.99. The disclosure for this sale can be found here. Insiders have sold a total of 20,646 shares of company stock valued at $714,898 over the last quarter. 2.30% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Arrowpoint Asset Management LLC raised its stake in Repligen by 33.1% in the fourth quarter. Arrowpoint Asset Management LLC now owns 150,525 shares of the biotechnology company’s stock worth $4,639,000 after buying an additional 37,443 shares in the last quarter. NN Investment Partners Holdings N.V. raised its stake in Repligen by 1.9% in the fourth quarter. NN Investment Partners Holdings N.V. now owns 39,300 shares of the biotechnology company’s stock worth $1,211,000 after buying an additional 715 shares in the last quarter. Macquarie Group Ltd. raised its stake in Repligen by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock worth $9,852,000 after buying an additional 264,659 shares in the last quarter. Rhumbline Advisers raised its stake in Repligen by 4.2% in the third quarter. Rhumbline Advisers now owns 62,801 shares of the biotechnology company’s stock worth $1,896,000 after buying an additional 2,530 shares in the last quarter. Finally, Comerica Bank raised its stake in Repligen by 5.7% in the fourth quarter. Comerica Bank now owns 35,963 shares of the biotechnology company’s stock worth $1,112,000 after buying an additional 1,951 shares in the last quarter. Institutional investors own 94.35% of the company’s stock.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with MarketBeat.com's FREE daily email newsletter.